NR1H4 and metabolic dysfunction-associated steatohepatitis: While side effects and lack of efficacy have led to the discontinuation of the MASH development program, the antifibrotic activity of OCA has been confirmed in various NASH/MASH trials, suggesting a potential role for OCA as part of combination regimens, although the recent approval of resmetirom and semaglutide for treatment of MASH is likely to impact the future development of FXR agonists.